Additional data is required by European regulatory authorities considering IDM Pharma's marketing authorisation application for mifamurtide

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1646, 2008-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance

By Permanand Govin   Mossialos Elias   McKee Martin  

Clinical Medicine, Vol. 6, Iss. 1, 2006-01 ,pp. : 87-90

Royal College Of Physicians

Access to resources Recommend Favorite

European marketing application for semuloparin withdrawn

By  

Reactions Weekly, Vol. 1, Iss. 1414, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

An additional Japanese marketing application for ubenimex [Bestatin] has been withdrawn

By  

Inpharma, Vol. 1, Iss. 1428, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Health Canada has announced the withdrawal of marketing authorisation for Prexige [lumiracoxib]

By  

Reactions Weekly, Vol. 1, Iss. 1173, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Refusal of the marketing authorisation for Sumatriptan Galpharm has been confirmed by the EMA's CHMP.

By  

Reactions Weekly, Vol. 1, Iss. 1380, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite